Results 191 to 200 of about 213,692 (219)

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi   +3 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai   +4 more
wiley   +1 more source

A unique finding of concomitant aneurysms of the right sinus of Valsalva and the right coronary artery treated conservatively. [PDF]

open access: yesCardiol J
Horosin G   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy